
ABSTRACT Background Clinical relapses in multiple sclerosis (MS) can occur without detectable inflammatory activity, termed apparent clinical events without radiological signs (ACES). The subsequent evolution of disability and inflammatory disease activity after ACES remains poorly characterized. Objectives To compare disability progression and subsequent clinical and radiological inflammatory activity in MS patients presenting with ACES versus relapses with active MRI (RAM). Methods Retrospective observational study including consecutive MS patients evaluated at a tertiary MS center in Brazil. Relapses were classified as ACES or relapses with active MRI (RAM) based on the presence of new T2/FLAIR or gadolinium‐enhancing lesions. Expanded Disability Status Scale (EDSS) at 6–12 and 24 months, clinical and radiological activity over two years were compared between groups. Results Among 54 patients, 25 (46%) presented with ACES and 29 (54%) with RAM. Patients with ACES were significantly older at relapse onset. Baseline disability, disease duration, functional system involvement, and disease‐modifying therapy use showed no statistically significant between‐group differences. EDSS at 6–12 and 24 months, 2‐year clinical relapse rates, and MRI activity also showed no statistically significant differences between ACES and RAM. Conclusions ACES were common and occurred predominantly in older patients with relapsing–remitting MS. Over 2 years, no statistically significant differences were observed in disability outcomes, clinical relapse rates, or radiological activity between ACES and RAM. Given the limited sample size, clinically meaningful differences cannot be excluded, and larger prospective studies are needed to clarify the long‐term significance of ACES.
ABSTRACT Background Efgartigimod has emerged as a treatment option for chronic inflammatory demyelinating polyneuropathy (CIDP); however, longitudinal electrophysiological changes during treatment and the clinical course after treatment withdrawal remain incompletely characterized. Case Presentation A woman in her 40s with CIDP showed a favorable but transient response to intravenous immunoglobulin and subsequently received subcutaneous efgartigimod as maintenance therapy. Clinical improvement was accompanied by marked electrophysiological recovery, including restoration of median sensory nerve action potentials and improvement in motor conduction parameters. After approximately 1 year of clinical stability, treatment was temporarily withdrawn, followed by clinical relapse approximately 3 weeks later. After efgartigimod reintroduction, improvement again became apparent after approximately the third administration, closely reproducing the initial treatment course. Conclusions The relapse after efgartigimod withdrawal and reproducible improvement after reintroduction support the potential role of efgartigimod as maintenance therapy in this patient. Serial nerve conduction studies may provide an objective adjunct for assessing electrophysiological response during treatment.
ABSTRACT Background Paraneoplastic and autoimmune retinopathies can cause progressive visual loss before structural ophthalmic or neurologic findings are diagnostic. Case Presentation A 66‐year‐old woman developed bilateral visual decline and was diagnosed with small‐cell lung cancer‐associated paraneoplastic neuroretinal dysfunction, with persistent blindness despite radiotherapy and plasma exchange. An 81‐year‐old woman with negative malignancy evaluation and abnormal multifocal electroretinography reported visual improvement after intravitreal dexamethasone. Conclusions These cases emphasize that nyctalopia, ring scotomas, and photopsias in the context of abnormal electroretinography should prompt retinal evaluation even when structural findings are limited, and that MOG‐ and AQP4‐associated optic neuritis must be explicitly excluded. Early malignancy assessment, immunologic testing, and individualized immunomodulatory treatment are essential; visual recovery is limited once irreversible retinal injury is established.
ABSTRACT Objectives To characterize real‐world barriers to chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) management in the Philippines and identify pragmatic patient‐centered solutions aligned with international guidance and local health‐system realities. Methods We conducted a survey‐informed qualitative expert‐panel study involving six Philippine neurologists from public and private tertiary centers. Data sources included review of EAN/PNS‐2021 CIDP guidelines, contemporary literature, and pre‐meeting survey results on local clinical practice followed by structured discussions. Findings were organized using a patient‐journey framework and analyzed thematically across clinical, operational, policy, and economic domains. Results Real‐world challenges were identified across three domains. Clinical: clinical mimics, variability in electrodiagnostic interpretation, limited test availability, and delayed referral; Operational: partial or variable treatment response, corticosteroid side‐effects, inpatient infusion logistics, and difficulties maintaining therapy; and Policy/economic: high out‐of‐pocket costs, limited reimbursement, procurement delays, and regional inequities. Experts described several key components of patient‐centered CIDP care, including the use of standardized diagnostic pathways, improved access to neurophysiological testing, increased disease awareness, and structured monitoring using disability and impairment scales. Additional elements included the incorporation of patient‐reported outcomes, shared decision‐making, and individualized infusion and weaning strategies, and generation of local real‐world, cost‐effectiveness, budget‐impact, and patient‐reported outcome data. Conclusions This study identifies neurologist‐perceived clinical and system barriers affecting CIDP care across the patient journey in the Philippines. Findings support implementation of an evidence‐based patient‐centered framework aligned with international guidelines but adapted for the Philippine healthcare system. Such a framework may improve diagnosis, streamline treatment, and enhance equitable access.